ATE368859T1 - Diagnostisches verfahren zur vorhersage von nierentransplantations-abstossung - Google Patents
Diagnostisches verfahren zur vorhersage von nierentransplantations-abstossungInfo
- Publication number
- ATE368859T1 ATE368859T1 AT04716242T AT04716242T ATE368859T1 AT E368859 T1 ATE368859 T1 AT E368859T1 AT 04716242 T AT04716242 T AT 04716242T AT 04716242 T AT04716242 T AT 04716242T AT E368859 T1 ATE368859 T1 AT E368859T1
- Authority
- AT
- Austria
- Prior art keywords
- diagnostic method
- transplant rejection
- kidney transplant
- predicting kidney
- predicting
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT000058A ITFI20030058A1 (it) | 2003-03-06 | 2003-03-06 | Formulazioni farmaceutiche contenenti tiazolidinedioni |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE368859T1 true ATE368859T1 (de) | 2007-08-15 |
Family
ID=32948189
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04716242T ATE368859T1 (de) | 2003-03-06 | 2004-03-02 | Diagnostisches verfahren zur vorhersage von nierentransplantations-abstossung |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060287372A1 (de) |
| EP (2) | EP1601355B1 (de) |
| JP (1) | JP2006519799A (de) |
| AT (1) | ATE368859T1 (de) |
| AU (1) | AU2004216823B2 (de) |
| CA (1) | CA2518199A1 (de) |
| CY (1) | CY1108098T1 (de) |
| DE (1) | DE602004007895T2 (de) |
| DK (1) | DK1601355T3 (de) |
| ES (1) | ES2290678T3 (de) |
| IT (1) | ITFI20030058A1 (de) |
| PL (1) | PL1601355T3 (de) |
| PT (1) | PT1601355E (de) |
| WO (1) | WO2004078175A2 (de) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0420722D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
| ITFI20040243A1 (it) * | 2004-11-25 | 2005-02-25 | Paola Romagnani | Metodo diagnostico per la previsione di rigetto di organo trapiantato |
| GB0504206D0 (en) * | 2005-03-01 | 2005-04-06 | Glaxo Group Ltd | Combination therapy |
| AR059898A1 (es) | 2006-03-15 | 2008-05-07 | Janssen Pharmaceutica Nv | Derivados de 3-ciano-piridona 1,4-disustituida y su uso como moduladores alostericos de los receptores mglur2 |
| PL2001469T3 (pl) | 2006-03-16 | 2012-10-31 | Metabolic Solutions Dev Co Llc | Analogi tiazolidynodionu |
| TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
| TW200845978A (en) | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
| TW200927731A (en) | 2007-09-14 | 2009-07-01 | Ortho Mcneil Janssen Pharm | 1,3-disubstituted-4-phenyl-1H-pyridin-2-ones |
| CN101801951B (zh) | 2007-09-14 | 2013-11-13 | 杨森制药有限公司 | 1’,3’-二取代的-4-苯基-3,4,5,6-四氢-2h,1’h-[1,4’]二吡啶-2’-酮 |
| KR20100065191A (ko) | 2007-09-14 | 2010-06-15 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | １,３-이치환된 ４-(아릴-ｘ-페닐)-１ｈ-피리딘-２-온 |
| ES2637794T3 (es) | 2007-11-14 | 2017-10-17 | Janssen Pharmaceuticals, Inc. | Derivados de imidazo[1,2-A]piridina y su uso como moduladores alostéricos positivos de receptores MGLUR2 |
| RU2510396C2 (ru) | 2008-09-02 | 2014-03-27 | Янссен Фармасьютикалз, Инк. | 3-азабицикло[3.1.0]гексильные производные в качестве модуляторов метаботропных глутаматных рецепторов |
| BRPI0920354A2 (pt) | 2008-10-16 | 2017-06-27 | Addex Pharmaceuticals Sa | derivados de indol e benzomorfolina como moduladores de receptores de glutamato metabotrópicos |
| AU2009319387B2 (en) | 2008-11-28 | 2012-05-10 | Addex Pharma S.A. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
| MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
| RS53075B (en) | 2009-05-12 | 2014-04-30 | Janssen Pharmaceuticals Inc. | 1,2,4-TRIAZOLO [4,3-A] PYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OR PREVENTION OF NEUROLOGICAL AND PSYCHIATRIC DISORDERS |
| JP5707390B2 (ja) | 2009-05-12 | 2015-04-30 | ジャンセン ファーマシューティカルズ， インコーポレイテッド | １，２，４−トリアゾロ［４，３−ａ］ピリジン誘導体およびｍＧｌｕＲ２受容体の正のアロステリック調節因子としてのその使用 |
| EP2643320B1 (de) | 2010-11-08 | 2015-03-04 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridinderivate und ihre verwendung als positiv allosterische modulatoren des mglur2 receptors |
| EP2649069B1 (de) | 2010-11-08 | 2015-08-26 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazol[4,3-a]pyridinderivate und ihre verwendung als positive allosterische mglur2-rezeptormodulatoren |
| EP2661435B1 (de) | 2010-11-08 | 2015-08-19 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazol[4,3-a]pyridinderivate und ihre verwendung als positive allosterische mglur2-rezeptormodulatoren |
| JO3368B1 (ar) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 6، 7- ثاني هيدرو بيرازولو [5،1-a] بيرازين- 4 (5 يد)- اون واستخدامها بصفة منظمات تفارغية سلبية لمستقبلات ميجلور 2 |
| JO3367B1 (ar) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | مركبات 2،1، 4- ثلاثي زولو [3،4-a] بيريدين واستخدامها بصفة منظمات تفارغية موجبة لمستقبلات ميجلور 2 |
| DK3431106T3 (da) | 2014-01-21 | 2021-03-15 | Janssen Pharmaceutica Nv | Kombinationer omfattende positive allosteriske modulatorer eller orthosteriske agonister af metabotrop glutamaterg subtype 2-receptor og anvendelse af disse |
| ES2860298T3 (es) | 2014-01-21 | 2021-10-04 | Janssen Pharmaceutica Nv | Combinaciones que comprenden moduladores alostéricos positivos del receptor glutamatérgico metabotrópico de subtipo 2 y su uso |
| US20190350907A1 (en) * | 2017-01-16 | 2019-11-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for reducing cd95- mediated cell motility |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0767790B1 (de) * | 1994-06-20 | 2001-12-12 | Takeda Chemical Industries, Ltd. | Kondensierte imidazolderivate, ihre herstellung und verwendung |
| KR20000016074A (ko) * | 1996-05-31 | 2000-03-25 | 가와무라 요시부미 | 자기면역질환 치료제 |
| GB9611947D0 (en) * | 1996-06-07 | 1996-08-07 | Glaxo Group Ltd | Medicaments |
| WO2000030628A2 (en) * | 1998-11-20 | 2000-06-02 | Genentech, Inc. | Method of inhibiting angiogenesis |
| US6369098B1 (en) * | 1999-10-05 | 2002-04-09 | Bethesda Pharmaceuticals, Inc. | Dithiolane derivatives |
| CA2393136A1 (en) * | 1999-11-30 | 2001-06-07 | Oxo Chemie Ag | Evaluating and predicting clinical outcomes by gene expression analysis |
| WO2001062238A2 (en) * | 2000-02-24 | 2001-08-30 | San Diego State University | Ppar gamma agonists for the treatment of liver inflammatory disorders |
| US20020019344A1 (en) * | 2000-02-26 | 2002-02-14 | Pershadsingh Harrihar A. | Methods of preventing allograft rejection |
| US20020018776A1 (en) * | 2000-04-14 | 2002-02-14 | Millennium Pharmaceuticals, Inc. | Method of treating graft rejection using inhibitors of CXCR3 function |
| FR2823225B1 (fr) * | 2001-04-04 | 2004-09-17 | Pierre Desreumaux | Utilisation de composes modulant l'activite de l'heterodimere rxr-ppar a titre de medicament pour le traitement de l'hepatite c, et procede de criblage correspondant |
| US7244555B2 (en) * | 2002-05-14 | 2007-07-17 | Renovak Inc | Systems and methods for identifying organ transplant risk |
-
2003
- 2003-03-06 IT IT000058A patent/ITFI20030058A1/it unknown
-
2004
- 2004-03-02 WO PCT/EP2004/002069 patent/WO2004078175A2/en active IP Right Grant
- 2004-03-02 EP EP04716242A patent/EP1601355B1/de not_active Expired - Lifetime
- 2004-03-02 AT AT04716242T patent/ATE368859T1/de not_active IP Right Cessation
- 2004-03-02 EP EP07109545A patent/EP1830191A3/de not_active Withdrawn
- 2004-03-02 ES ES04716242T patent/ES2290678T3/es not_active Expired - Lifetime
- 2004-03-02 US US10/548,514 patent/US20060287372A1/en not_active Abandoned
- 2004-03-02 JP JP2006504502A patent/JP2006519799A/ja active Pending
- 2004-03-02 AU AU2004216823A patent/AU2004216823B2/en not_active Ceased
- 2004-03-02 DK DK04716242T patent/DK1601355T3/da active
- 2004-03-02 PT PT04716242T patent/PT1601355E/pt unknown
- 2004-03-02 DE DE602004007895T patent/DE602004007895T2/de not_active Expired - Lifetime
- 2004-03-02 PL PL04716242T patent/PL1601355T3/pl unknown
- 2004-03-02 CA CA002518199A patent/CA2518199A1/en not_active Abandoned
-
2007
- 2007-10-15 CY CY20071101331T patent/CY1108098T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004078175A2 (en) | 2004-09-16 |
| DE602004007895T2 (de) | 2008-04-17 |
| EP1601355A2 (de) | 2005-12-07 |
| US20060287372A1 (en) | 2006-12-21 |
| EP1830191A2 (de) | 2007-09-05 |
| DK1601355T3 (da) | 2007-12-17 |
| PL1601355T3 (pl) | 2007-12-31 |
| EP1830191A3 (de) | 2007-10-03 |
| CY1108098T1 (el) | 2014-02-12 |
| DE602004007895D1 (de) | 2007-09-13 |
| WO2004078175A3 (en) | 2004-12-09 |
| JP2006519799A (ja) | 2006-08-31 |
| ES2290678T3 (es) | 2008-02-16 |
| EP1601355B1 (de) | 2007-08-01 |
| PT1601355E (pt) | 2007-11-15 |
| AU2004216823A1 (en) | 2004-09-16 |
| ITFI20030058A1 (it) | 2004-09-07 |
| CA2518199A1 (en) | 2004-09-16 |
| AU2004216823B2 (en) | 2009-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE368859T1 (de) | Diagnostisches verfahren zur vorhersage von nierentransplantations-abstossung | |
| CY1116107T1 (el) | Ενωσεις για χρηση στην αγωγη αυτοανοσων παθησεων, ανοσο-αλλεργικων παθησεων και απορριψης μεταμοσχευσης οργανων ή ιστων | |
| ATE457989T1 (de) | Bi- und trizyklische substituierte phenyl- methanone als inhibitoren von glycin-i (glyt-1)- transportern zur behandlung der alzheimer- krankheit | |
| DE602004020332D1 (de) | Neue heterozyklische verbindungen, die sich für die behandlung von entzündlichen und allergischen erkrankungen eignen: verfahren zu deren herstellung und pharmazeutische zusammensetzungen, die diese enthalten | |
| DE60335552D1 (de) | Neue zusammensetzung und verfahren zur behandlung von immunerkrankungen | |
| DE602004022036D1 (de) | Verfahren zur behandlung von atherosklerose, dyslipidämie und verwandten erkrankungen und pharmazeutische zusammensetzungen | |
| DK1131096T3 (da) | Anti-CD20-antistofbehandling af patienter, der modtager knoglemarvs- eller periferisk blodstamcelletransplantationer | |
| DE60317918D1 (de) | Tricyclische verbindungen zur behandlung von entzündlichen- und allergischen erkrankungen: verfahren zu deren herstellung und sie enthaltende pharmazeutische zusammensetzungen | |
| DE502004009299D1 (de) | Verfahren zur Herstellung von Niobsuboxid | |
| EA200700202A1 (ru) | Гетероарильные соединения в качестве бетамиметиков для лечения заболеваний дыхательных путей | |
| EA200300929A1 (ru) | Новые лекарственные композиции на основе антихолинергических средств и ингибиторов pde-iv | |
| MA27855A1 (fr) | Composition contenant un inhibiteur de pde4 et un inhibiteur de pde5 | |
| ATE409176T1 (de) | 1-phenylalkancarbonsäurederivate zur behandlung neurodegenerativer erkrankungen | |
| ATE389401T1 (de) | Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung | |
| DE60225561D1 (de) | Indanessigsäure-derivate und ihre verwendung als pharmazeutische mittel, zwischenprodukten und verfahren zur herstellung | |
| ATE313540T1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
| DE60233221D1 (de) | Verfahren zur reinigung höherer diamantstrukturartiger verbindungen sowie diese enthaltenden zubereitungen | |
| DE602004020042D1 (de) | er SSRI zur Behandlung von Stimmungs- oder Angststörungen | |
| DE60136748D1 (de) | Verfahren und zusammensetzungen zur behandlung von augenerkrankungen | |
| DE50304687D1 (de) | Verfahren zur herstellung von benzophenonen | |
| DE60216457D1 (de) | Carbamate verbindungen zur behandlung oder verhutung von psychotischen krankheiten | |
| ATE503476T1 (de) | Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch infektion mit yersinia spp ausgelöst sind | |
| IL159479A (en) | Glycopeptides, their preparation and use in the diagnosis or therapeutic treatment of multiple sclerosis | |
| DE60107888D1 (de) | Beta-Interferon zur Behandlung von Immunerkrankungen | |
| DE60300201D1 (de) | Verfahren zur Herstellung von Polyetherpolyolen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1601355 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |